Nonmotor disturbances in Parkinson's disease

Neurodegenerative Diseases

Volumn 8, Issue 3, 2011, Pages 95-108

  Bassetti, Claudio L ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Anxiety; Depression; Diagnosis; Fatigue; Nonmotor disturbances; Parkinson's disease; Quality of life

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; BENZODIAZEPINE; CHOLINESTERASE INHIBITOR; CLONAZEPAM; CLOZAPINE; DOMPERIDONE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; FLUDROCORTISONE; HISTAMINE H3 RECEPTOR ANTAGONIST; MELATONIN; MEMANTINE; MIDODRINE; MIRTAZAPINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXYBATE SODIUM; PRAMIPEXOLE; PYRIDOSTIGMINE; RASAGILINE; REBOXETINE; RIVASTIGMINE; ROPINIROLE; ROTIGOTINE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM;

ANXIETY DISORDER; APATHY; BEDTIME DOSAGE; BLADDER DYSFUNCTION; BRAIN DEPTH STIMULATION; COGNITIVE BEHAVIORAL STRESS MANAGEMENT; COGNITIVE DEFECT; DAYTIME SOMNOLENCE; DELUSION; DEMENTIA; DEPRESSION; DIFFUSE LEWY BODY DISEASE; EXCESSIVE DAYTIME SLEEPINESS; FATIGUE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPERSOMNIA; IMPULSE CONTROL DISORDER; INSOMNIA; NEUROPSYCHIATRY; ORTHOSTATIC HYPOTENSION; PAIN; PANIC; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; PERIODIC LIMB MOVEMENT DISORDER; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER; RESTLESS LEGS SYNDROME; REVIEW; SENSORY DYSFUNCTION; SEXUAL DYSFUNCTION; SLEEP DISORDER; SLEEP DISORDERED BREATHING; SLEEP WALKING; SMELLING DISORDER; STRIDOR;

ANXIETY; DEPRESSION; FATIGUE; HUMANS; PAIN; PARKINSON DISEASE; QUALITY OF LIFE; REM SLEEP BEHAVIOR DISORDER;

EID: 79953306427     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000316613     Document Type: Review

References (137)

1. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al: International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006; 21: 916-923. (Pubitemid 44184590)
2. Goetz C, Tilley B, Shaftman S, et al: Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008; 23: 2129-2170.
3. Zesiewicz TA, Sullivan KL, Arnulf I, et al: Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 16: 924-931.
4. Aarsland D, Marsh L, Scharg A: Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; 24: 2175-2186.
5. Berney A, Vingerhoets F, Perrin A, Guex P, Villemure JG, Burkhard PR, Benkelfat C, Ghika J: Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive seres of 24 patients. Neurology 2002; 59: 1427- 1428.
6. Weintraub D, Moberg P, Duda J, et al: Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004; 52: 784-788. (Pubitemid 38596500)
7. Schrag A, Jahanshahi M, Quinn NP: What contributes to quality of life in patients with Parkinson disease. J Neurol Neurosurg Psychiatry 2000; 69: 289-290.
8. Remy P, Doder M, Lees AJ, et al: Depression in Parkinson's disease: loss of dopamine and noradeanline innervation in the limbic system. Brain 2005; 128: 1314-1322. (Pubitemid 40826185)
9. Bejjani BP, Damier P, Arnulf I, et al: Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med 1999; 340: 1476-1480. (Pubitemid 29220547)
10. Chaudhuri KR, Healy DG, Schapira AHV: Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-245. (Pubitemid 43238347)
11. Chaudhuri KR, Schapira AHV: Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464-474.
12. Menza M, Dobkin MM, Marin H, et al: A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-892.
13. Rabinak CA, Nirenberg MJ: Dopamine agonist withdrawal syndrome in Parkinson disease. Arch Neurol 2010; 67: 58-63.
14. Giovannoni G, O'Sullivan JD, Turner K, Manson AJ, Lees AJL: Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 2000; 68: 423-428. (Pubitemid 30248740)
15. Kulisevsky J, Pagirabarraga J, Martinez- Corral M: Changes in artistic style and behavior in Parkinson's disease: dopamine and creativity. J Neurol 2009; 265: 816-819.
16. Voon V, Fernagut PO, Wickens J, et al: Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol 2010; 8: 1140-1149.
17. Weintraub D, Hoops S, Shea JA, et al: Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease. Mov Disord 2010; 24: 1461-1467.
18. Weintraub D: Dopamine and impulse control disorders in Parkinson's disease. Ann Neurol 2008; 64:S93-S100.
19. Weintraub D, Koester J, Potenza MN, et al: Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-595.
20. Abler B, Hahlbrock R, Unrath A, et al: Atrisk for pathological gambling: imaging neural reward processing under chronic dopamine agonists. Brain 2009; 132: 2396-2402.
21. Salas RE, Allen RA, Earley CJ, Gamaldo CE: A case of compulsive behaviors observed in a restless legs syndrome patient treated with a dopamine agonist. Sleep 2009; 32: 587-588.
22. Kimber TE, Thompson PD, Kiley MA: Resolution of dopamine dysregulation syndrome following cessation of dopamine agonist therapy in Parkinson's disease. J Clin Neurosci 2008; 15: 205-208. (Pubitemid 50009897)
23. Williams DR, Lees AJ: Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-610. (Pubitemid 41317294)
24. Lippa CF, Duda JE, Grossmann M, et al: DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007; 68: 812-819. (Pubitemid 46568532)
25. Fénelon G, Mahieux F, Huon R, Ziégler M: Hallucinations in Parkinson's disease. Brain 2000; 123: 733-745.
26. Fénelon G, Thobois S, Bonnet AM, Broussole E, Tison F: Tactile hallucinations in Parkinson's disease. J Neurol 2002; 249: 1699-1703.
27. Goetz CG, Wuu J, Curgian LM, Leurgans S: Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology 2005; 64: 81-86. (Pubitemid 40082941)
28. Schmeichel AM, Buchhalter LC, Low PA, et al: Mesopontine cholinergic neuron involvement in Lewy body dementia and multiple system atrophy. Neurology 2008; 70: 368- 373. (Pubitemid 351653399)
29. Maurage CA, Ruchoux MM, de Vos R, Surguchov A, Destee A: Retinal involvement in dementia with Lewy bodies: a clue to hallucinations? Ann Neurol 2003; 54: 542-547. (Pubitemid 37176555)
30. Cubo E, Martin PM, Martin-Gonzalez JA, et al: Motor laterality asymmetry and nonmotor symptoms in Parkinson's disease. Mov Disord 2010; 25: 70-75.
31. Ravina BM, Marder K, Fernandez HH, et al: Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov Disord 2007; 22: 1061-1068. (Pubitemid 47067214)
32. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999; 353: 2041- 2042.
33. Parkinson SG: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340: 757-763.
34. Aarsland D, Andersen K, Larsen JP, et al: Prevalence and characteristics of dementia in Parkinson disease. Arch Neurol 2003; 60: 387-392. (Pubitemid 36314364)
35. Hely MA, Reid WG, Adena MA, et al: The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008; 30: 837-844.
36. Ferman TJ, Smith GE, Boeve BF, et al: DLB fluctuations. Specific features that reliably differentiate DLB from AD and normal aging. Neurology 2004; 62: 181-187. (Pubitemid 38167122)
37. Compta Y, Santamaria J, Ratti L, et al: Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 2009; 132: 3308-3317.
38. Jellinger KA: Significance of brain lesions in Parkinson disease dementia and Lewy body dementia. Front Neurol Neurosci 2009; 24: 114-125.
39. Klein JC, Eggers C, Kalbe E, et al: Neurotransmitter changes in dementia with Lewy bodies and Parkinson disease dementia in vivo. Neurology 2010; 74: 885-992.
40. Kalbe E, Calabrese P, Kohn N, et al: Screening for cognitive deficits in Parkinson's disease with the Parkinson neuropsychometric dementia assessment (PANDA) instrument. Parkinsonism Relat Disord 2008; 14: 93-101. (Pubitemid 351726305)
41. Kulisevsky J, Pagonabarraga J: Cognitive impairment in Parkinson's disease: tools for diagnosis and assessment. Mov Disord 2009; 24: 1103-1110.
42. Hoops S, Nazem S, Siderowf AD, et al: Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. Neurology 2009; 73: 1738-1745.
43. Bassetti CL, Fuhr P, Monsch A, et al: Definition, Diagnose und Management der Parkinson-Demenz: Empfehlungen der Swiss Parkinson's Disease Dementia Study Group. Schweiz Arch Neurol Psychiatr 2007; 157: 155-165.
44. Riedel O, Klotsche J, Spottke A, et al: Cognitive impairment in 873 patients with idiopathic Parkinson's disease. Results from the German Study on Epidemiology of Parkinson's Disease with Dementia (GEPAD). J Neurol 2008; 255: 255-264.
45. Cooper JA, Sagar HJ, Doherty SM, et al: Different effects of dopaminergic and anticholinergic therapies on cognitive and motor functions in Parkinson's disease. A followup study of untreated patients. Brain 1992; 115: 1701-1725. (Pubitemid 23054861)
46. Marsh L, Biglan K, Gerstenhaber M, Williams JR: Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009; 24: 277-282.
47. Ravina B, Putt M, Siderowf AD, et al: Donepezil for dementia in Parkinson's disease: a randomized, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005; 76: 934-939. (Pubitemid 40909549)
48. Emre M, Aarsland D, Albanese A, et al: Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004; 351: 2509-2518. (Pubitemid 39603164)
49. Aarsland D, Ballard C, Walker Z, et al: Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 2009; 8: 613-618.
50. Bassetti C: Parkinson dementia. Schweiz Arch Neurol 2007;158:155-165.
51. Ondo WG, Dat Vuong K, Khan H, Atassi F, Kwak C, Jankovic J: Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 2001; 57: 1392-1395.
52. Gjerstad MD, Boeve BF, Wentzel-Larsen T, Aarsland D, Larsen JP: Occurrence and clinical correlates of REM sleep behavior disorder in patiens with Parkinson's disease over time. J Neurol Neurosurg Psychiatry 2008; 79: 387-391. (Pubitemid 351441491)
53. Schenck CH, Bundlie SR, Patterson AL, Mahowald MW: Rapid eye movement sleep behavior disorder. JAMA 1987; 257: 1786-1789.
54. Gagnon JF, Vendette M, Postuma RB, et al: Mild cognitive impairment in rapid eye movement sleep behavior disorder and Parkinson's disease. Ann Neurol 2009; 66: 39-47.
55. Schenck CH, Bundlie SR, Mahowald MW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46: 388-393.
56. Iranzo A, Molinuevo JL, Santamaria J, et al: Rapid-eye movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006; 5: 572-577. (Pubitemid 43867426)
57. Poryazova R, Oberholzer M, Bassetti CL: REM sleep behavior disorder in Parkinson's disease: a questionnaire based survey. Submitted for publication.
58. Benninger D, Waldvogel D, Bassetti CL: REM sleep behavior disorder is not linked to postural instability and gait dysfunction in Parkinson's disease. Mov Disord, in press.
59. Boeve BF: Pathophysiology of REM sleep behavior disorder and relevance to neurodegenerative disease. Brain 2007; 130: 2770-2788. (Pubitemid 350033955)
60. Albin RL, Koeppe RA, Chervin RD, et al: Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000; 55: 1410-1412.
61. Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, et al: The REM sleep behavior disorder screening questionnaire - a new diagnostic instrument. Mov Disord 2007; 22: 2386-2393. (Pubitemid 351155985)
62. Onofrj M, Luciano AL, Thomas A, Iacono D, D'Andreamatteo G: Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism Neurology 2003; 60: 113-114.
63. Poryazova R, Waldvogel D, Bassetti CL: Sleepwalking in patients with Parkinson disease. Arch Neurol 2007; 64: 1-4.
64. Shulman L, Singer C, Bean J, et al: Internal tremor in patients with Parkinson's disease. Mov Disord 1996; 11: 3-7. (Pubitemid 26008556)
65. Ondo WG, Vuong KD, Jankovic J: Exploring the relationship between Parkinson disease and restless legs syndrome. Neurology 2002; 59: 421-424. (Pubitemid 34208151)
66. Peralta CM, Frauscher B, Deppi K, Wolf E, Wenning GK, Hégl B, Poewe W: Restless legs syndrome in Parkinson's disease. Mov Disord 2009; 24: 2076-2080.
67. Iranzo A, Comella CL, Santamaria J, Oertel W: Restless legs syndrome in Parkinson's disease and other neurodegenerative diseases of the central nervous system. Mov Disord 2007; 22:S424-S430.
68. Happe S, Pirker W, Klösch G, et al: Periodic limb movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter. J Neurol 2003; 250: 83-86. (Pubitemid 36206689)
69. Frucht S, Rogers J, Greene P, et al: Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999; 52: 1908-1910. (Pubitemid 29260911)
70. Arnulf I: Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9: 185- 200. (Pubitemid 40694186)
71. Valko P, Bassetti CL, Waldvogel D: Fatigue and excessive daytime sleepiness in idiopathic Parkinson's disease differently correlate with motor symptoms, depression and dopaminergic treatment. Mov Disord, in press.
72. Poryazova R, Benninger D, Waldvogel D, Bassetti CL: Excessive daytime sleepiness in Parkinson's disease: characteristics and determinants. Eur Neurol 2010; 63: 129-135.
73. Roth T, Rye D, Borchen LD, et al: Assessment of sleepiness and unintended sleep in Parkinson's disease patients taking dopamine agonists. Sleep Med 2003; 4: 275-280. (Pubitemid 36974806)
74. Ulivelli M, Rossi S, Lombardi C, et al: Polysomnographic characterization of pergolide- induced sleep attacks in idiopathic PD. Neurology 2002; 58: 462-465. (Pubitemid 34150925)
75. Paus S, Brecht HM, Köster J, Seegr G, Klockgether T, Wüllner U: Sleep attacks, daytime sleepiness, and dopamine agonists in Parkinson's disease. Mov Disord 2003; 18: 659-667. (Pubitemid 36790281)
76. Rye D, Johnston L, Watts R, Bliwise D: Juvenile Parkinsons' disease with REM sleep behavior disorder, sleepiness and daytime REM onset. Neurology 1999; 53: 1868-1870. (Pubitemid 29530371)
77. Fronczeck R, Overeem S, Lee SY, et al: Hypocretin (orexin) loss in Parkinson's disease. Brain 2007; 130: 1577-1585. (Pubitemid 47355929)
78. Overeem N, Van Hilten JJ, Ripley B, Mignot E, Nishino H, Lammers C: Normal hypocretin- 1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 2002; 58: 498-499. (Pubitemid 34150937)
79. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti C: Parkinsonism with excessive daytime sleepiness - a narcolepsylike disorder? J Neurol 2005; 252: 139-145. (Pubitemid 40385585)
80. Baumann CR, Scammell TE, Bassetti CL: Parkinson's disease, sleepiness and hypocretin/ orexin. Brain 2008; 131:e91. (Pubitemid 351294704)
81. Arnulf I, Bonnet AM, Damier P, et al: Hallucinations, REM sleep, and Parkinson's disease. A medical hypothesis. Neurology 2000; 55: 281-288. (Pubitemid 30604632)
82. Rye DB, Bliwise DL, Dihenia B, Gurecki P: Daytime sleepiness in Parkinson's disease. J Sleep Res 2000; 9: 63-69.
83. Högl B, Saletu M, Brandauer E, et al: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a doubleblind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25: 905-909. (Pubitemid 35424536)
84. Adler CH, Caviness JN, Hentz JG, Lind M, Tiede J: Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003; 18: 287-293. (Pubitemid 36410825)
85. Ondo WG, Foyle R, Atassi F, Jankovic J: Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neruosurgery Psychiatry 2005; 76: 1636-1639. (Pubitemid 41697625)
86. Ondo WG, Perkins T, Swick T, et al: Sodium oxybate for excessive daytime sleepiness in Parkinson's disease. Arch Neurol 2008; 65: 1337-1340.
87. Lin JS, Dauvilliers Y, Arnulf I, et al: An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008; 30: 74-83.
88. Pedersen KF, Alves G, Aarsland P, Larsen JP: Occurrence and risk factors for apathy in Parkinson disease: a 4-year prospective longitudinal study. J Neurol Neurosurg and Psychiatry 2009; 80: 1279-1282.
89. Starkstein SE, Merello M, Jorge R, et al: The syndromal validity and nosological position of apathy in Parkinson's disease. Mov Disord 2009; 24: 1211-1216.
90. Dujardin K, Sockeel D, Delliaux M, et al: Apathy may herald cognitive decline and dementia in Parkinson's disease. Mov Disord 2009; 24: 2391-2397.
91. Le Jeune F, Drapier D, Bourguignon A, et al: Subthalamic nucleus stimulation in Parkinson disease induces apathy: a PET study. Neurology 2009; 73: 1746-1751.
92. Valko PP, Bassetti CL, Bloch K, Held U, Baumann CR: Validation of the fatigue severity scale in a Swiss cohort. Sleep 2008; 31: 1601- 1607.
93. Friedman JH, Alves G, Hagell P, et al: Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease. Mov Disord 2010; 25: 805-822.
94. Lou JS, Dimitrova DM, Park BS, et al: Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo controlled pilot study. Clin Neuropharmacol 2009; 32: 305-310.
95. Caap-Ahlgren M, Dehlin O: Insomnia and depressive symptoms in patients with Parkinson's disease. Relationship to health related quality of life. An interview study of patients living at home. Arch Gerontol Geriatr 2001; 32: 23-33. (Pubitemid 32201141)
96. Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP: Insomnia in Parkinson's disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 2007; 78: 476-479. (Pubitemid 46662894)
97. Chaudhuri KR, Pal S, DiMarco A, Whately- Smith C, Bridgman K, Mathew RJ, Pezzela FR, Forbes A, Högl B, Trenkwalder C: The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 629-635. (Pubitemid 35448845)
98. De Cock VC, Vidhailet M, Arnulf I: Sleep disturbances in patients with parkinsonism. Nat Clin Pract Neurol 2008; 4: 254-266. (Pubitemid 351639546)
99. Arnulf I, Bejjani BP, Garma L, Bonnet AM, Houeto JL, Damier P, Derenne JP, Agid Y: Improvement of sleep architecture in PD with subthalamic nucleus stimulation. Neurology 2000; 55: 1732-1734.
100. Paus S, Schmitz-Häbsch T, Wüllner U, et al: Bright light therapy in Parkinson's disease: a pilot study. Mov Disord 2007; 22: 1495- 1498. (Pubitemid 47280641)
101. Willis GL, Turner EJ: Primary and secondary features of Parkinson's disease improve with strategic exposure to bright light: a case series study. Chronobiol Int 2007; 24: 521-537. (Pubitemid 47026954)
102. Maria B, Sophia S, Michalis M, et al: Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med 2003; 97: 1151-1157. (Pubitemid 37185119)
103. Diederich NJ, Vaillant M, Leischen M, et al: Sleep apnea syndrome in Parkinson's disease. A case-control study in 49 patients. Mov Disord 2005; 20: 1413-1418. (Pubitemid 43072648)
104. Munschauer FE, Loh L, Bannister R, Newsom- Davis J: Abnormal respiration and sudden death during sleep in multiple system atrophy with autonomic failure. Neurology 1990; 40: 677-679. (Pubitemid 20139100)
105. Hartmann DE: Stridor during dystonia phases of Parkinson's disease. J Neurol Neurosurg Psychiatry 1988; 51: 161.
106. Iranzo A, Santamaria J, Tolosa E: Continuous positive air pressure eliminates nocturnal stridor in multisystem atrophy. Lancet 2000; 356: 1329-1330.
107. Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Montrastuc JL: Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 63: 584-589. (Pubitemid 27489221)
108. Oka H, Yoshioka M, Onouchi K, et al: Characteristics of orthostatic hypotension in Parkinson's disease. Brain 2007; 130: 2425- 2432. (Pubitemid 47327636)
109. Shy GM, Drager GA: A neurological syndrome associated with orthostatic hypotension: a clinical-pathologic study. Arch Neurol 1960; 2: 511-527.
110. Martinolli M, Korpelainen JT, Korpelainen R, et al: Orthostatic hypotension, balance and falls in Parkinson's disease. Mov Disord 2009; 24: 745-751.
111. Jamnadas-Khoda J, Koshy S, Mathis CJ, et al: Are current recommendations to diagnose orthostatic hypotension in Parkinson's disease satisfactory? Mov Disord 2009; 24: 1747-1751.
112. Visser M, Marinus J, Stiggelbout AM, van Hiltern JJ: Assessment of autonomic dysfunction in Parkinson's disease: The SCOPA-AUT. Mov Disord 2004; 19: 1306-1312. (Pubitemid 39534547)
113. Mathias CJ, Kimber J: Treatment of postural hypotension. J Neurol Neurosurg Psychiatry 1998; 65: 285-289. (Pubitemid 28408239)
114. Young TM, Mathias CJ: The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry 2004; 75: 1737-1741. (Pubitemid 39611476)
115. Ransmayr GN, Holliher S, Schletterer K, et al: Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer's disease. Neurology 2008; 70: 299-303. (Pubitemid 351156810)
116. Blackett H, Walker R, Wood B: Urinary dysfunction in Parkinson's disease: a review. Parkinsonism Relat Disord 2009; 15: 81-87.
117. Fritsche HM, Ganzer R, Schlaier J, et al: Acute urinary retention in two patients after subthalamic nucleus deep brain stimulation (STN-DBS) for the treatment of advanced Parkinson's disease. Mov Disord 2009; 24: 1553-1554.
118. Pavlakis AJ, Siroky MB, Goldstein I, Krane RJ: Neurourologic findings in Parkinson's disease. J Urol 1983; 129: 80-83.
119. Giannantoni A, Rossi A, Mearini E, et al: Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182: 1453- 1457.
120. Mostile G, Jankovic J: Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009; 15(suppl 3):S224-S232.
121. Savica R, Carlin JM, Grossardt BR, et al: Medical records documentation of constipation preceding Parkinson's disease: a case-control study. Neurology 2009; 24: 1752-1758.
122. Evatt ML, Chaudhuri KR, Chou KL, et al: Dysautonomia rating scales in Parkinson's disease: sialorrhea, dysphagia, and constipation - critique and recommendations by movement disorders task force on rating scales for Parkinson's disease. Mov Disord 2009; 24: 635-646.
123. Kalf JG, de Swart BJ, Borm GF, et al: Prevalence and definition of drooling in Parkinson's disease: a systematic review. J Neurol 2009; 256: 1391-1396.
124. Ondo W, Hunter C, Moore WS: A doubleblind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62: 37-40. (Pubitemid 38082867)
125. Arbouw ME, Movig KL, Koopmann M, et al: Glycopyrrolate for sialorrhea in Parkinson disease: a randomized, double-blind, crossover trial. Neurology 2010; 74: 1203- 1207.
126. Goldstein DS, Sewell L, Holmes C: Association of anosmia with autonomic failure in Parkinson disease. Neurology 2010; 74: 245-251.
127. Double KL, Rowe DB, Hayes M, et al: Identifying the pattern of olfactory deficits in Parkinson disease using the brief smell identification test. Arch Neurol 2003; 60: 545-549. (Pubitemid 36427969)
128. Ross GW, Petrivitch H, Abbott RD, et al: Association of olfactory dysfunction with risk of future Parkinson's disease. Ann Neurol 2008; 63: 167-173. (Pubitemid 351355295)
129. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J: Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006; 66: 845-851. (Pubitemid 43739758)
130. Braak H, Del Tredici K, Rüb U, et al: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211. (Pubitemid 36007810)
131. Hahner A, Boesveldt S, Berendse HW: Prevalence of smell loss in Parkinson's disease - a multicenter study. Parkinsonism Relat Disord 2009; 15: 490-494.
132. Snider SR, Fahn S, Isgreen WP, Cote LJ: Primary sensory symptoms in parkinsonism. Neurology 1976; 26: 423-429.
133. Defazio G, Berardelli A, Fabbrini G, et al: Pain as a nonmotor symptom of Parkinson's disease: evidence from a case-control study. Arch Neurol 2008; 65: 1191-1194.
134. Beiske AG, Loge JH, Ronningen A, Svensson E: Pain in Parkinson's disease: prevalence and characteristics. Pain 2009; 141: 173-177.
135. Ford B, Louis ED, Green P, Fahns S: Oral and genital pain syndromes in Parkinson's disease. Mov Disord 1996; 11: 421-426. (Pubitemid 26235780)
136. Cantello R: Analgesic action of methylphenidate on parkinsonian sensory symptoms. Arch Neurol 1988; 45: 973-976.
137. Kim HJ, Paek SH, Kim JY, et al: Chronic subthalamic deep brain stimulation improves pain in Parkinson disease. J Neurol 2008; 255: 1889-1894.